Conclusion: Following surgical trauma, the middle ear mucosa healed well without packing or with PUF packing material, and hearing was not affected. In contrast AGS packing material showed hearing loss at low frequencies and osteogenesis.
Methods:
We conducted a retrospective chart review of all individuals aged 60 years or older who underwent a first CI from 1999-2011 at Johns Hopkins to abstract data on postoperative follow-up and complications. Statistical analyses comparing observed complication frequencies were performed using goodness-of-fit Fisher exact tests.
Results: From 1999 From -2011 individuals 60 years or older received a first cochlear implant at Johns Hopkins. The mean age at implantation was 72.7 years (range 60-94.9 years) and the median duration of follow-up was 4.8 years (range 0.1-12.5 years). There were a total of 42 minor complications in 41 patients (9.2%) and 36 major complications in 21 patients (4.7%). There were no cases of meningitis or postoperative facial paralysis. Seventeen patients (3.8%) required surgical device removal. Complication rates did not differ between individuals 60-75 years and those 75 years or older except for balance problems which were slightly more prevalent in the older cohort (9.5% vs 4.9%, P = .05).
Conclusion:
Our results demonstrate that CI in older adults has a safety profile comparable to CI in younger adults and children. We suggest that concerns for increased postoperative complications in patients of advanced age should not be considered when determining CI candidacy.
Otology/Neurotology Complications and Clinical Analysis of Cochlear implatations Jianhua Qiu, MD, PhD (presenter)
Objective: To investigate complications of cochlear implantation for prevention and therapy.
Method: Retrospective study at a tertiary referral center. The patients (n = 673) who received cochlear implants in our department between 2000 and 2011 were followed up (range, 6 months to 10 years). All complications were systematically reviewed, and their causes were analyzed for prevention and therapy.
Results: There were a total of 33 complications (4.9%). The minor were 26 cases (3.9%), including postoperative subcutaneous hematoma in 14 cases, acute otitis media in 2 cases, postoperative wound infection in 2 cases, delayed facial paralysis in 1 case, clonic facial spasm in 1 case, and severe dizziness in 6 cases. The major were 7 cases (1.1%), including cerebrospinal fluid leakage in 2 cases, implant-related infection and extrusion in 2 cases, tympanic membrane perforation induced electrode exposed in 1 case, implantation failure due to cochlear ossification in 1 case, and magnet displacement in 1 case.
Conclusion:
Cochlear implantation is a safe and reliable operation, but it is still a serious problem to lower the incidence of complications.
Otology/Neurotology Cytokines induced by Gentamicin and Sepsis in the Cochlea
Lourdes Quintanilla-Dieck, MD (presenter); Barbara Larrain; Dennis R. Trune, PhD; Peter Steyger, MD Objective: The mechanism by which sepsis-induced inflammation enhances aminoglycoside trafficking into the cochlea remains poorly understood. This study sought to determine if protein expression of inflammatory-mediated cytokines in the cochlea is modulated by systemic sepsis and/or drug treatment.
Method: Three groups of mice received 1 of the following treatments: gentamicin, lipopolysaccharide for sepsis induction, or both gentamicin and lipopolysaccharide. A fourth group served as controls. After sacrifice, cochleae were collected and homogenized for protein extraction. This was followed by an enzyme-linked immunosorbent assay for analysis of 16 inflammatory-mediated cytokines.
Results: There was substantial elevation in cochlear expression of multiple cytokines in mice treated with bacteria-derived lipopolysaccharide, with or without gentamicin. The most salient cytokines were interleukin-1α, interleukin-6, monocyte chemotactic protein-1, and macrophage inflammatory protein-α. Gentamicin alone did not induce a significant inflammatory response, compared to lipopolysaccharide. This suggests that in the cochlea, specific pro-inflammatory cytokines are massively produced during a systemic infection, but not in the presence of aminoglycosides as the sole insult. Given that these cytokines increase permeability across bloodendothelial barriers, permitting transendothelial migration of inflammatory cells, they may also enhance aminoglycoside trafficking and contribute to its ototoxicity.
Conclusion: Aminoglycosides are usually prescribed for prophylaxis or systemic bacterial infection. The latter induces a pro-inflammatory state that could enhance aminoglycoside uptake by cochlear tissues. Unveiling the mechanisms mediated by sepsis that contribute to cochlear uptake of aminoglycosides will aid the development of strategies to ameliorate or prevent this devastating side-effect.
